Omeros Shares Climb As FDA Grants Orphan Drug Status To Blood Disorder Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Omeros Corporation’s (NASDAQ: OMER) lead asset OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).